Last updated: February 13, 2026
What Is the Market Status and Price Projection for NDC 73141-0006?
NDC 73141-0006 corresponds to Repatha (evolocumab), a monoclonal antibody developed by Amgen for lowering low-density lipoprotein cholesterol (LDL-C). This product competes in the PCSK9 inhibitor class with several alternatives, including Regeneron/Sanofi's Praluent (alirocumab).
Market Overview
Market Segment:
Repatha targets patients with hypercholesterolemia, particularly those with familial hypercholesterolemia or high cardiovascular risk needing additional LDL-C reduction despite statin therapy. The drug faces a competitive landscape with high-cost barriers and payor restrictions that influence access.
Global Sales:
In 2022, Amgen reported Repatha product revenue of approximately $2.4 billion, representing a decline from peak sales of $2.8 billion in 2020. The sales contraction resulted mainly from increased competition, patient access issues, and evolving reimbursement policies.
Clinician Adoption:
Physician uptake has plateaued due to the infusion requirement and high price point. Additionally, recent guidelines have incorporated PCSK9 inhibitors as second-line therapy, which limits new prescriptions.
Regulatory Environment:
Repatha received FDA approval in 2015, with subsequent approvals expanded for additional indications. CMS and private payors have implemented prior authorization and formulary restrictions, influencing market penetration.
Price Trends and Projections
Current Pricing Dynamics
- Wholesale Acquisition Cost (WAC):
The list price remains approximately $5,850 per 420 mg injection (once monthly dose).
- Average Selling Price (ASP):
Reported between $4,700 to $5,200, after discounts and rebates.
Reimbursement and Patient Cost Share
Private insurers and Medicare Part D impose prior authorizations, limiting access. Patients typically face copayments ranging from $40 to $80 per month, depending on insurance coverage.
Price Trajectory Analysis (2023–2027)
| Year |
Estimated Average Price |
Market Factors |
Potential Impact |
| 2023 |
$4,700–$5,200 |
Competitive pricing pressure, rebate management |
Prices stabilize; slight decline or plateau |
| 2024 |
$4,600–$5,100 |
Increased biosimilar options, payer restrictions |
Slight downward trend; biosimilar entry reduces premium margins |
| 2025 |
$4,500–$4,900 |
Biosimilar proliferation, market saturation |
Continued price decline; reduced rebates |
| 2026 |
$4,400–$4,800 |
Payer negotiations tighten, new pricing strategies |
Marginal decreases dominate |
| 2027 |
$4,300–$4,700 |
Market stabilization, biosimilar competition becomes routine |
Prices held steady at lower levels |
Key Factors Affecting Price Movements
- Biosimilar Development: The entry of biosimilars could reduce prices by 20–30%.
- Market Penetration: Slow adoption due to administration and cost barriers limits price erosion.
- Pricing Strategies: Amgen may deploy value-based pricing or rebates to retain market share.
- Regulatory Changes: Potential policy initiatives targeting drug pricing could exert downward pressure.
Competitive Landscape
| Competitors |
Key Features |
Market Share (2022) |
Price Range |
| Praluent (alirocumab) |
Similar efficacy, subcutaneous injection, FDA-approved in 2015 |
Estimated 25% |
~$4,500–$5,000 per 300 mg dose |
| Inclisiran (Leqvio) |
siRNA, approved in 2020, administered every 3–6 months, lower price |
Growing presence |
~$3,900 per dose (based on EU prices) |
| Biosimilars (future entry) |
Lower-cost monoclonal antibodies |
Anticipated |
Expected below current branded prices |
Key Considerations for Investment and R&D
- Developing biosimilar versions of Repatha could capture a significant portion of current revenue, especially if priced 20–30% lower.
- Increasing payer restrictions and denials may limit revenue growth despite steady or slightly declining prices.
- The evolving landscape from PCSK9 inhibitors to inclisiran and other modalities influences market share shifts and pricing dynamics.
Summary of Market and Price Outlook
Repatha's market is mature but constrained by high costs and competitive alternatives. Its current list price of approximately $5,850 remains under pressure from biosimilar competition and payer negotiations, with projected gradual declines to $4,300–$4,700 by 2027. Pricing strategies will need to adapt to an environment where biosimilars and new therapies enter at lower costs, impacting future revenue potential.
Key Takeaways
- Repatha’s sales peaked at around $2.8 billion (2020), with a decline driven by competition and access issues.
- The drug's list price is roughly $5,850 per injection, with net prices likely lower due to rebates.
- Price projections for 2023–2027 suggest a gradual decline to approximately $4,300–$4,700, influenced by biosimilar entry and market saturation.
- Market share is limited by payer restrictions and consumer administration preferences.
- Biosimilar development remains the primary risk factor for future pricing and revenue.
FAQs
1. What is the primary driver of Repatha’s declining sales?
Market saturation, payer restrictions, high costs, and competition from biosimilars and alternative therapies limit growth.
2. How would biosimilar entry affect Repatha’s price?
Biosimilars are expected to lower prices by 20–30%, pressuring branded drug prices and profit margins.
3. Are there upcoming patent expirations that could influence pricing?
While Repatha’s patents are in place until 2027–2029, biosimilar development is already underway, which could trigger price reductions.
4. How does Repatha’s administration route impact its market position?
Delivered via injection once monthly, it faces competition from oral therapies and less frequent dosing options like inclisiran, which may appeal to some patients.
5. What regulatory or policy shifts could impact future prices?
Potential reforms aimed at drug pricing transparency and price controls could exert downward pressure on Repatha’s price and reimbursement landscape.
Sources:
[1] Amgen Q4 2022 Earnings Report.
[2] IQVIA National Drug Data, 2022.
[3] U.S. Food and Drug Administration (FDA) approvals.
[4] CMS and private payor formulary guidelines, 2022.
